Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008)

Waite, Angharad H. K., Jackson, Karen, Gregor, Thomas P. and Krick, Erika L. (2013) Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008). Javma-Journal of the American Veterinary Medical Association, 242 8: 1104-1109. doi:10.2460/javma.242.8.1104


Author Waite, Angharad H. K.
Jackson, Karen
Gregor, Thomas P.
Krick, Erika L.
Title Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008)
Journal name Javma-Journal of the American Veterinary Medical Association   Check publisher's open access policy
ISSN 0003-1488
1943-569X
Publication date 2013-04
Sub-type Article (original research)
DOI 10.2460/javma.242.8.1104
Open Access Status Not Open Access
Volume 242
Issue 8
Start page 1104
End page 1109
Total pages 6
Place of publication Schaumburg, IL United States
Publisher American Veterinary Medical Association
Language eng
Formatted abstract
Objective—To evaluate the clinical response rate, progression-free survival time, overall survival time, and possible prognostic factors associated with a cyclophosphamide-, vincristine-, and prednisone (COP)-based chemotherapy protocol in cats with lymphoma.
Design—Retrospective case series.
Animals—114 cats with lymphoma.
Procedures—Medical records of cats receiving a weekly COP-based chemotherapy protocol from 1998 to 2008 at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania were evaluated for information regarding signalment, anatomic site of involvement, cell morphology, treatment, and outcome. Retroviral status, baseline weight, substage, anatomic location, dose delays, dose reductions, and response to treatment were evaluated for prognostic importance.
Results—The majority of cases (94 [82.4%]) were substage b, and the most common anatomic site was the gastrointestinal tract (57 [50%]). Clinical response rate after the first chemotherapy cycle was 47.4%. Response to treatment was significantly associated with progression-free survival time and overall survival time, whereas substage was significantly associated with progression-free survival time. The median progression-free survival time and overall survival time were 65.5 and 108 days, respectively. Compared with nonresponders, responders had significantly longer median progression-free survival time (364 vs 31 days) and median overall survival time (591 vs 73 days).
Conclusions and Clinical Relevance—Clinical response after 1 cycle of COP-based chemotherapy was predictive for progression-free survival time and overall survival time in cats with lymphoma; therefore, response after 1 cycle of chemotherapy could be used to guide decisions about further treatment. No new prognostic factors were identified. 
Keyword Feline Gastrointestinal Lymphoma
Malignant-Lymphoma
Chemotherapy
Lymphosarcoma
Survival
Leukemia
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Veterinary Science Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 17 May 2016, 14:24:50 EST by Annette Winter on behalf of Learning and Research Services (UQ Library)